Glucose Metabolism Disorders  >>  Adlyxin (lixisenatide)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adlyxin (lixisenatide) / Sanofi
LIRA-LIXIâ„¢, NCT01973231 / 2012-004984-27: Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

Completed
4
404
Europe
liraglutide, lixisenatide
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
11/14
11/14
NCT02200991: Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Completed
4
136
Japan
LIXISENATIDE AVE0010, Sitagliptin, Januvia, Insulin glargine HOE901, Lantus
Sanofi
Type 2 Diabetes Mellitus
11/15
11/15
NCT02049034 / 2013-002826-22: Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

Completed
4
8
Europe
Lixisenatide, GLP-1 agonist, Lyxumia, Placebo
University of Surrey, Sanofi
Type 2 Diabetes
01/16
01/16

Download Options